Glaxosmithkline | GSK - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 12.54B 474M 2026-03
Amgen USD 6.89B 415M 2025-12
AstraZeneca USD 12.61B 225M 2026-03
Aurora Cannabis CAD 46.62M 14.33M 2025-12
Bausch Health Companies USD 2B 67M 2025-12
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Canopy Growth CAD 21.47M 434K 2025-12
Corcept Therapeutics USD 162.02M 37.56M 2026-03
Drreddys Laboratories INR 46.81B 10.24B 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
GlaxoSmithKline GBP 5.75B 429M 2026-03
Glaxosmithkline GBP 8.75B 2.92B 2025-09
J&J USD 17.24B 642M 2026-03
Merck USD 10.85B 2.57B 2025-12
Novartis USD 10.07B 184M 2026-03
Pacira USD 126.64M 15.61M 2026-03
Perrigo USD 325.5M 36.7M 2026-03
Pfizer USD 11.04B 1.24B 2026-03
Phibro Animal Health USD 133.5M 12.6M 2025-12
Prestige Brands USD 157.37M 5.79M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
Supernus Pharmaceuticals USD 129.36M 34.68M 2026-03
Takeda JPY 688.84B 101.71B 2026-03
Teva Pharmaceutical Industries USD 2.11B 547M 2026-03
Zoetis USD 1.62B 20M 2026-03